Skip to content
drillr.ai
Sign up

TARS

Tarsus Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · US

$78.09
−1.19%
Ask drillr

  • Sep 10, 2026, 20:12 UTC

    Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals via a merger, with Alkeus surviving as a wholly-owned subsidiary, for $270 million in cash plus 2,908,692 shares of common stock and up to $350 million in milestone payments.

  • Aug 26, 2026, 14:42 UTC

    The U.S. Federal Trade Commission granted early termination of the waiting period under the HSR Act for Tarsus's acquisition of Alkeus.

    Source:

  • Aug 6, 2026, 11:03 UTC

    Tarsus reported second quarter 2026 financial results, with XDEMVY net product sales of $173.9 million, up more than 69% year-over-year.

    Source:

  • Aug 6, 2026, 11:02 UTC

    Tarsus Pharmaceuticals announced an oversubscribed $125.0 million private placement equity financing with qualified institutional buyers and accredited investors.

    Source:

  • Aug 6, 2026, 11:01 UTC

    Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals, adding the Phase 3 oral investigational drug gildeuretinol (ALK-001) for Stargardt disease to its pipeline.

    Source:

  • Jul 13, 2026, 20:05 UTC

    Tarsus Pharmaceuticals announced the departure of Chief Commercial Officer Aziz Mottiwala and the appointment of Neera Clase as Interim Chief Commercial Officer.

    Source:

  • Jul 11, 2026, 14:02 UTC

    Tarsus Pharmaceuticals acquired iRenix Medical, Inc., adding IRX-101 to its pipeline and entering the retina market.

    Source:

  • Jul 8, 2026, 20:05 UTC

    Tarsus acquired iRenix Medical and its late-stage asset IRX-101.

    Source: